Page last updated: 2024-11-11

cgp 71683 a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CGP 71683 A: selective NPY Y(5) receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5312114
CHEMBL ID17645
CHEMBL ID195380
CHEBI ID92555
SCHEMBL ID326665
MeSH IDM0300081
PubMed CID9849276
CHEMBL ID582005
SCHEMBL ID225992
MeSH IDM0300081

Synonyms (65)

Synonym
gtpl1562
cgp 71683a
NCGC00165960-01
NCGC00159542-01
cgp 71683
bdbm50089038
L000175
cgp-71683a
CHEMBL17645 ,
bdbm50166561
naphthalene-1-sulfonic acid {4-[(4-amino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide
CHEMBL195380 ,
gnf-pf-1864 ,
n-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide
NCGC00159542-02
e4901ja9jd ,
192321-23-6
unii-e4901ja9jd
BRD-K31912990-003-01-0
SCHEMBL326665
1-naphthalenesulfonamide, n-((4-(((4-amino-2-quinazolinyl)amino)methyl)cyclohexyl)methyl)-, trans-
cgp-71683a free base
1-naphthalenesulfonamide, n-((trans-4-(((4-amino-2-quinazolinyl)amino)methyl)cyclohexyl)methyl)-
CHEBI:92555
NCGC00371082-01
cgp71683
BCP25968
cgp-71683a; cgp 71683a; cgp71683a;cgp 71683;cgp-71683
Q27075929
Q27276849
cgp71683a
CHEMBL582005
cgp 71683 hydrochloride
cgp 71683 a
unii-45b73p82a3
45b73p82a3 ,
1-naphthalenesulfonamide, n-((trans-4-(((4-amino-2-quinazolinyl)amino)methyl)cyclohexyl)methyl)-, hydrochloride (1:1)
192322-50-2
1-naphthalenesulfonamide, n-((4-(((4-amino-2-quinazolinyl)amino)methyl)cyclohexyl)methyl)-, monohydrochloride, trans-
1-naphthalenesulfonamide, n-((trans-4-(((4-amino-2-quinazolinyl)amino)methyl)cyclohexyl)methyl)-, monohydrochloride
SCHEMBL225992
n-[[trans-4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide hydrochloride
AKOS024456984
AS-75042
n-{[(1r,4r)-4-{[(4-aminoquinazolin-2-yl)amino]methyl}cyclohexyl]methyl}naphthalene-1-sulfonamide hydrochloride
J-012430
cgp 71683 hcl
n-rel-(((1r,4r)-4-(((4-aminoquinazolin-2-yl)amino)methyl)cyclohexyl)methyl)naphthalene-1-sulfonamide hydrochloride
ZB0040
n-(((1r,4r)-4-(((4-aminoquinazolin-2-yl)amino)methyl)cyclohexyl)methyl)naphthalene-1-sulfonamide hydrochloride
BCP20871
cgp71683 hydrochloride
cgp 71683a; cgp71683a; cgp-71683 hcl
CS-0029390
HY-107723
cgp71683hcl
D80521
1-naphthalenesulfonamide, n-[[trans-4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-, hydrochloride (1:1)
Q27258822
cgp 71683a hcl
cgp 71683a hydrochloride
cgp-71683a hcl
192322-50-2 (hcl)
n-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride
cgp71683a hcl

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sulfonic acid derivative
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.98110.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency46.68270.004023.8416100.0000AID485290
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
phosphopantetheinyl transferaseBacillus subtilisPotency48.44610.141337.9142100.0000AID1490; AID2701; AID2707
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.01120.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency4.77240.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency3.37860.00108.379861.1304AID1645840
glucocerebrosidaseHomo sapiens (human)Potency22.38720.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546; AID2551
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency28.18380.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency4.77240.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency4.77240.01238.964839.8107AID1645842
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency28.18380.00638.235039.8107AID881
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency4.77240.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency4.77240.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.09700.00001.44217.3470AID242562
Neuropeptide Y receptor type 1Homo sapiens (human)IC50 (µMol)8.37000.00020.70318.3700AID146428
Aquaporin-1Homo sapiens (human)IC50 (µMol)2.70002.70002.70002.7000AID1801571
Neuropeptide Y receptor type 2Homo sapiens (human)IC50 (µMol)1.89000.00020.74804.4000AID146600
Neuropeptide Y receptor type 4Homo sapiens (human)IC50 (µMol)5.74005.74005.74005.7400AID146734
Neuropeptide Y receptor type 5Homo sapiens (human)IC50 (µMol)0.00250.00130.33932.7000AID146743; AID146745; AID146912; AID242549
Neuropeptide Y receptor type 5Rattus norvegicus (Norway rat)IC50 (µMol)0.00140.00140.00170.0021AID146890
Melanin-concentrating hormone receptor 1Homo sapiens (human)IC50 (µMol)3.50000.00050.23633.5000AID253487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (186)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
outflow tract morphogenesisNeuropeptide Y receptor type 1Homo sapiens (human)
glucose metabolic processNeuropeptide Y receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerNeuropeptide Y receptor type 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayNeuropeptide Y receptor type 1Homo sapiens (human)
neuropeptide signaling pathwayNeuropeptide Y receptor type 1Homo sapiens (human)
locomotory behaviorNeuropeptide Y receptor type 1Homo sapiens (human)
feeding behaviorNeuropeptide Y receptor type 1Homo sapiens (human)
regulation of blood pressureNeuropeptide Y receptor type 1Homo sapiens (human)
sensory perception of painNeuropeptide Y receptor type 1Homo sapiens (human)
regulation of multicellular organism growthNeuropeptide Y receptor type 1Homo sapiens (human)
renal water homeostasisAquaporin-1Homo sapiens (human)
glomerular filtrationAquaporin-1Homo sapiens (human)
renal water transportAquaporin-1Homo sapiens (human)
potassium ion transportAquaporin-1Homo sapiens (human)
water transportAquaporin-1Homo sapiens (human)
cell volume homeostasisAquaporin-1Homo sapiens (human)
intracellular water homeostasisAquaporin-1Homo sapiens (human)
fibroblast migrationAquaporin-1Homo sapiens (human)
positive regulation of fibroblast migrationAquaporin-1Homo sapiens (human)
carbon dioxide transportAquaporin-1Homo sapiens (human)
glycerol transmembrane transportAquaporin-1Homo sapiens (human)
sensory perception of painAquaporin-1Homo sapiens (human)
cellular homeostasisAquaporin-1Homo sapiens (human)
cGMP-mediated signalingAquaporin-1Homo sapiens (human)
lateral ventricle developmentAquaporin-1Homo sapiens (human)
pancreatic juice secretionAquaporin-1Homo sapiens (human)
nitric oxide transportAquaporin-1Homo sapiens (human)
establishment or maintenance of actin cytoskeleton polarityAquaporin-1Homo sapiens (human)
cerebrospinal fluid secretionAquaporin-1Homo sapiens (human)
secretory granule organizationAquaporin-1Homo sapiens (human)
cellular response to UVAquaporin-1Homo sapiens (human)
transepithelial water transportAquaporin-1Homo sapiens (human)
carbon dioxide transmembrane transportAquaporin-1Homo sapiens (human)
wound healingAquaporin-1Homo sapiens (human)
odontogenesisAquaporin-1Homo sapiens (human)
negative regulation of apoptotic processAquaporin-1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAquaporin-1Homo sapiens (human)
lipid digestionAquaporin-1Homo sapiens (human)
positive regulation of angiogenesisAquaporin-1Homo sapiens (human)
positive regulation of saliva secretionAquaporin-1Homo sapiens (human)
positive regulation of fibroblast proliferationAquaporin-1Homo sapiens (human)
camera-type eye morphogenesisAquaporin-1Homo sapiens (human)
defense response to Gram-negative bacteriumAquaporin-1Homo sapiens (human)
multicellular organismal-level water homeostasisAquaporin-1Homo sapiens (human)
corticotropin secretionAquaporin-1Homo sapiens (human)
establishment of localization in cellAquaporin-1Homo sapiens (human)
renal water absorptionAquaporin-1Homo sapiens (human)
cellular response to hydrogen peroxideAquaporin-1Homo sapiens (human)
cellular response to inorganic substanceAquaporin-1Homo sapiens (human)
cellular response to mechanical stimulusAquaporin-1Homo sapiens (human)
cellular response to copper ionAquaporin-1Homo sapiens (human)
cellular response to mercury ionAquaporin-1Homo sapiens (human)
cellular response to retinoic acidAquaporin-1Homo sapiens (human)
cellular response to cAMPAquaporin-1Homo sapiens (human)
cellular response to hypoxiaAquaporin-1Homo sapiens (human)
cellular response to salt stressAquaporin-1Homo sapiens (human)
cellular hyperosmotic responseAquaporin-1Homo sapiens (human)
cellular response to dexamethasone stimulusAquaporin-1Homo sapiens (human)
cellular response to nitric oxideAquaporin-1Homo sapiens (human)
potassium ion transmembrane transportAquaporin-1Homo sapiens (human)
metanephric descending thin limb developmentAquaporin-1Homo sapiens (human)
metanephric proximal straight tubule developmentAquaporin-1Homo sapiens (human)
metanephric proximal convoluted tubule segment 2 developmentAquaporin-1Homo sapiens (human)
metanephric glomerulus vasculature developmentAquaporin-1Homo sapiens (human)
ammonium transmembrane transportAquaporin-1Homo sapiens (human)
hyperosmotic responseAquaporin-1Homo sapiens (human)
outflow tract morphogenesisNeuropeptide Y receptor type 2Homo sapiens (human)
cardiac left ventricle morphogenesisNeuropeptide Y receptor type 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayNeuropeptide Y receptor type 2Homo sapiens (human)
neuropeptide signaling pathwayNeuropeptide Y receptor type 2Homo sapiens (human)
locomotory behaviorNeuropeptide Y receptor type 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayNeuropeptide Y receptor type 4Homo sapiens (human)
neuropeptide signaling pathwayNeuropeptide Y receptor type 4Homo sapiens (human)
positive regulation of acute inflammatory responseNeuropeptide Y receptor type 5Homo sapiens (human)
negative regulation of acute inflammatory response to antigenic stimulusNeuropeptide Y receptor type 5Homo sapiens (human)
outflow tract morphogenesisNeuropeptide Y receptor type 5Homo sapiens (human)
cardiac left ventricle morphogenesisNeuropeptide Y receptor type 5Homo sapiens (human)
neuropeptide signaling pathwayNeuropeptide Y receptor type 5Homo sapiens (human)
negative regulation of glutamate secretionNeuropeptide Y receptor type 5Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicNeuropeptide Y receptor type 5Homo sapiens (human)
eating behaviorNeuropeptide Y receptor type 5Homo sapiens (human)
negative regulation of apoptotic processNeuropeptide Y receptor type 5Homo sapiens (human)
positive regulation of smooth muscle cell proliferationNeuropeptide Y receptor type 5Homo sapiens (human)
generation of ovulation cycle rhythmNeuropeptide Y receptor type 5Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuropeptide Y receptor type 5Homo sapiens (human)
synaptic signaling via neuropeptideNeuropeptide Y receptor type 5Homo sapiens (human)
chemical synaptic transmissionNeuropeptide Y receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayNeuropeptide Y receptor type 5Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
generation of precursor metabolites and energyMelanin-concentrating hormone receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationMelanin-concentrating hormone receptor 1Homo sapiens (human)
feeding behaviorMelanin-concentrating hormone receptor 1Homo sapiens (human)
positive regulation of calcium ion transportMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuropeptide signaling pathwayMelanin-concentrating hormone receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (59)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
peptide YY receptor activityNeuropeptide Y receptor type 1Homo sapiens (human)
pancreatic polypeptide receptor activityNeuropeptide Y receptor type 1Homo sapiens (human)
neuropeptide Y receptor activityNeuropeptide Y receptor type 1Homo sapiens (human)
protein bindingNeuropeptide Y receptor type 1Homo sapiens (human)
neuropeptide receptor activityNeuropeptide Y receptor type 1Homo sapiens (human)
neuropeptide bindingNeuropeptide Y receptor type 1Homo sapiens (human)
intracellularly cGMP-activated cation channel activityAquaporin-1Homo sapiens (human)
potassium channel activityAquaporin-1Homo sapiens (human)
water transmembrane transporter activityAquaporin-1Homo sapiens (human)
protein bindingAquaporin-1Homo sapiens (human)
ammonium transmembrane transporter activityAquaporin-1Homo sapiens (human)
potassium ion transmembrane transporter activityAquaporin-1Homo sapiens (human)
glycerol transmembrane transporter activityAquaporin-1Homo sapiens (human)
water channel activityAquaporin-1Homo sapiens (human)
transmembrane transporter activityAquaporin-1Homo sapiens (human)
nitric oxide transmembrane transporter activityAquaporin-1Homo sapiens (human)
carbon dioxide transmembrane transporter activityAquaporin-1Homo sapiens (human)
identical protein bindingAquaporin-1Homo sapiens (human)
ephrin receptor bindingAquaporin-1Homo sapiens (human)
peptide YY receptor activityNeuropeptide Y receptor type 2Homo sapiens (human)
neuropeptide Y receptor activityNeuropeptide Y receptor type 2Homo sapiens (human)
calcium channel regulator activityNeuropeptide Y receptor type 2Homo sapiens (human)
protein bindingNeuropeptide Y receptor type 2Homo sapiens (human)
signaling receptor activityNeuropeptide Y receptor type 2Homo sapiens (human)
pancreatic polypeptide receptor activityNeuropeptide Y receptor type 4Homo sapiens (human)
G protein-coupled receptor activityNeuropeptide Y receptor type 4Homo sapiens (human)
peptide hormone bindingNeuropeptide Y receptor type 4Homo sapiens (human)
neuropeptide bindingNeuropeptide Y receptor type 4Homo sapiens (human)
neuropeptide Y receptor activityNeuropeptide Y receptor type 5Homo sapiens (human)
pancreatic polypeptide receptor activityNeuropeptide Y receptor type 5Homo sapiens (human)
peptide YY receptor activityNeuropeptide Y receptor type 5Homo sapiens (human)
neuropeptide bindingNeuropeptide Y receptor type 5Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
signaling receptor bindingMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuropeptide receptor activityMelanin-concentrating hormone receptor 1Homo sapiens (human)
melanin-concentrating hormone receptor activityMelanin-concentrating hormone receptor 1Homo sapiens (human)
hormone bindingMelanin-concentrating hormone receptor 1Homo sapiens (human)
G protein-coupled receptor activityMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuropeptide bindingMelanin-concentrating hormone receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (48)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneNeuropeptide Y receptor type 1Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 1Homo sapiens (human)
neuron projectionNeuropeptide Y receptor type 1Homo sapiens (human)
plasma membraneAquaporin-1Homo sapiens (human)
nucleusAquaporin-1Homo sapiens (human)
cytoplasmAquaporin-1Homo sapiens (human)
plasma membraneAquaporin-1Homo sapiens (human)
brush borderAquaporin-1Homo sapiens (human)
basal plasma membraneAquaporin-1Homo sapiens (human)
basolateral plasma membraneAquaporin-1Homo sapiens (human)
apical plasma membraneAquaporin-1Homo sapiens (human)
axonAquaporin-1Homo sapiens (human)
brush border membraneAquaporin-1Homo sapiens (human)
nuclear membraneAquaporin-1Homo sapiens (human)
sarcolemmaAquaporin-1Homo sapiens (human)
apical part of cellAquaporin-1Homo sapiens (human)
extracellular exosomeAquaporin-1Homo sapiens (human)
ankyrin-1 complexAquaporin-1Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 2Homo sapiens (human)
ciliumNeuropeptide Y receptor type 2Homo sapiens (human)
non-motile ciliumNeuropeptide Y receptor type 2Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 4Homo sapiens (human)
membraneNeuropeptide Y receptor type 4Homo sapiens (human)
neuron projectionNeuropeptide Y receptor type 4Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 4Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 5Homo sapiens (human)
presynapseNeuropeptide Y receptor type 5Homo sapiens (human)
GABA-ergic synapseNeuropeptide Y receptor type 5Homo sapiens (human)
plasma membraneNeuropeptide Y receptor type 5Homo sapiens (human)
neuron projectionNeuropeptide Y receptor type 5Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneMelanin-concentrating hormone receptor 1Homo sapiens (human)
ciliumMelanin-concentrating hormone receptor 1Homo sapiens (human)
ciliary membraneMelanin-concentrating hormone receptor 1Homo sapiens (human)
non-motile ciliumMelanin-concentrating hormone receptor 1Homo sapiens (human)
neuron projectionMelanin-concentrating hormone receptor 1Homo sapiens (human)
plasma membraneMelanin-concentrating hormone receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID100242Compound was tested for reversal of NPY-induced inhibition of forskolin stimulated cAMP production in LM (tk-) cell2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID100241Compound was tested for NPY-induced intracellular Ca+2 mobilization in LM (tk-) cell2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID146890Compound was tested for rat Neuropeptide Y receptor type 52000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID253487Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 cells using [125I](Phe13, Tyr19) MCH2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.
AID146428Compound was tested for human Neuropeptide Y receptor type 12000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID146600Compound was tested for human Neuropeptide Y receptor type 22000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID242562Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-9122005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.
AID146912Human Neuropeptide Y5 receptor binding affinity2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis of new thiophene and benzo[b]thiophene hydrazide derivatives as human NPY Y(5) antagonists.
AID146745Compound was tested for its antagonistic activity against Neuropeptide Y receptor Y5 subtype stably expressed in LM(tk-)cells2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID146743Compound was tested for human Neuropeptide Y receptor type 52000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID146734Compound was tested for human Neuropeptide Y receptor type 42000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
AID242549Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYY2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.
AID1346388Rat Y5 receptor (Neuropeptide Y receptors)2003British journal of pharmacology, Aug, Volume: 139, Issue:7
Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1801571Stopped-flow Assay from Article 10.1111/cbdd.12713: \\Rapid Identification of Novel Inhibitors of the Human Aquaporin-1 Water Channel.\\2016Chemical biology & drug design, May, Volume: 87, Issue:5
Rapid Identification of Novel Inhibitors of the Human Aquaporin-1 Water Channel.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (9.38)18.2507
2000's18 (56.25)29.6817
2010's7 (21.88)24.3611
2020's4 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]